$IRD Cashflow Statement | Understand Stock

$IRD

$3.32 -$0.15 (4.32%) Close

$IRD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Depreciation
Non-cash acquired in-process research and development
Gain on note extinguishment
Non-cash interest on convertible notes
Non-cash interest on convertible notes - related party
Non-cash discount amortization on convertible notes
Non-cash discount amortization on convertible notes - related party
Fair value change in warrant and other derivative liabilities
Non-cash interest attributed to Series A warrant issuance
Issuance costs attributed to Series A warrants
Non-cash share settlement with investors
Receipt of investments related to license agreement
Warrant Financing costs
Non-cash interest
Non-cash share issuances
Unrealized loss from short-term investments
Acquired in-process research and development
Gain in connection with asset acquisition
Change in assets and liabilities:
Accounts receivable
Contract asset
Contract assets and unbilled receivables
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities

Net cash used in operating activities
Investing activities
Cash acquired in connection with asset acquisition
Cash received in connection with asset acquisition
Net cash provided by investing activities

Financing activities
Proceeds from pre-merger financing
Proceeds from issuance of common stock and pre-funded warrants in connection with the registered direct offering
Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement
Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement
Proceeds from issuance of common stock
Proceeds from issuance of convertible notes
Issuance costs attributed to equity instruments
Issuance costs attributed to common stock and convertible notes
Proceeds from short-term loan
Payments made on short-term loan principal
Settlement of Rexahn warrants
Proceeds from funding agreement, related party
Share repurchases for the payment of employee taxes
Exercise of warrants
Exercise of stock options
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Supplemental non-cash investing and financing transactions:
Non-cash reclassification of Series A warrant liability to equity
Non-cash conversion of convertible notes to common stock
Common stock and Series A preferred stock issued in connection with the asset acquisition
Net liabilities assumed in connection with asset acquisition
Non-cash issuance of common stock in connection with equity purchase agreement
Unpaid transaction costs in connection with asset acquisition
Net assets assumed in connection with asset acquisition
Unpaid issuance costs
Value of derivative established in connection with the equity purchase agreement
Conversion of Series A preferred stock into common stock
Reclass of warrant liabilities to equity upon exercise
Change in unpaid issuance costs

Comments